Positive HER-2 expression has been found to be an independent prognosticator of worse endometrial cancer patient survival in several studies [36,37,38,39,40], while a study of 315 patients with endometrioid histology endometrial cancer found no significant association of HER-2 expression with survival, stages I through IV cancer or other clinicopathologic features [41]. Here, ERBB2 is linked to endometrial cancer.